RxSight preliminary Q2 revenue $33.6M, down 4% YoY; cuts FY2025 guidance to $120-130M

RxSight, Inc.

2025-Q2 EPS reported -$0.49 revenue$71,531,000

Preliminary Q2 revenue ~$33.6M, down 4% YoY and 11% sequentially; LAL volume +13% YoY, LDD sales -49% YoY.
FY2025 revenue guidance slashed to $120-130M (from $160-175M), implying 7-14% decrease from 2024.
Gross margin guidance raised to 72-74% (from 71-73%); operating expense guidance $145-155M, up 7-14% YoY.
Installed LDD base of 1,084 units (+34% YoY); management cites underperformance and plans to refocus commercial strategy.
Cash $227.5M as of June 30, 2025, down $1.8M from March 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.